Immunocore (IMCR)
(Delayed Data from NSDQ)
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.09 USD
+0.20 (0.65%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $31.09 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth B Momentum B VGM
Zacks News
Immunocore Holdings PLC Sponsored ADR (IMCR) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.
Is a Surprise Coming for Immunocore (IMCR) This Earnings Season?
by Zacks Equity Research
Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Immunocore (IMCR) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Immunocore's (IMCR) Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak - its first-line treatment for metastatic uveal melanoma - and updates on its pipeline candidates.
Investors Heavily Search Immunocore Holdings PLC Sponsored ADR (IMCR): Here is What You Need to Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $57.61, moving -1.69% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $64.51, moving +1.9% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Surges 6.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $61.26 in the latest trading session, marking a -1.62% move from the prior day.
Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $63.52, moving +1.78% from the previous trading session.
Here is What to Know Beyond Why Immunocore Holdings PLC Sponsored ADR (IMCR) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Immunocore Holdings PLC Sponsored ADR (IMCR). This makes it worthwhile to examine what the stock has in store.
Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $60.69, moving +0.03% from the previous trading session.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $59.62, marking a -0.53% move from the previous day.
Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $59.13, moving -1.58% from the previous trading session.
Is Immunocore (IMCR) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Immunocore Holdings PLC Sponsored ADR (IMCR) and Allogene Therapeutics (ALLO) have performed compared to their sector so far this year.
Immunocore Holdings PLC Sponsored ADR (IMCR) Soars 6.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
by Zacks Equity Research
Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Exelixis (EXEL) Announces Preliminary Q4 and 2022 Results
by Zacks Equity Research
Exelixis (EXEL) reports preliminary revenues for the fourth quarter and 2022. It also provides guidance for 2023 and pipeline updates.
FATE To End Janssen Deal and Prioritize Pipeline Development
by Zacks Equity Research
FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.
Phathom (PHAT) Down on Regulatory Update on Vonoprazan NDA
by Zacks Equity Research
Phathom Pharmaceuticals, Inc. (PHAT) declines as the FDA decides to not take any action on Phathom's new drug application (NDA) for vonoprazan for treating erosive esophagitis.
Best Momentum Stocks to Buy for December 30th
by Zacks Equity Research
IMCR, RGA and VCISY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2022.
New Strong Buy Stocks for December 30th
by Zacks Equity Research
IMCR, RGA, LPLA, ACR and VCISY have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2022.
Kala Pharmaceuticals (KALA) Up as FDA Accepts IND for KPI-012
by Zacks Equity Research
The FDA accepts Kala Pharmaceuticals' (KALA) investigational new drug application for pipeline candidate KPI-012 for treating persistent corneal epithelial defect. Stock up.
ACER Down Despite FDA Nod for Urea Cycle Disorders Drug
by Zacks Equity Research
The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.